Dr. Alexander McGirr, MD
Claim this profileUniversity of Calgary
Studies Depression Treatment
Studies Suicide and Self-Harm
5 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Alexander McGirr, MD is currently running
TMS + D-Cycloserine
for Fibromyalgia
This trial tests a new treatment for fibromyalgia using magnetic brain stimulation combined with a medication. It aims to help adults with fibromyalgia who haven't found relief from other treatments. The treatment works by using magnets to change brain activity and the medication to boost this effect.
Recruiting0 awards Phase 29 criteria
iTBS + D-Cycloserine
for Suicidal Thoughts
Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives. Transcranial Magnetic Stimulation (TMS) is a non-invasive neurostimulation treatment for major depressive disorder, a mental health condition at high risk for suicide. It is well tolerated and effective. However, in the child and youth population, it does not appear to be superior to sham-TMS. Therefore, strategies for enhancing TMS outcomes are required. Over time, TMS can change the function of brain regions important in depression to reduce the symptoms of depression, including suicidal ideation. The investigators believe this occurs through a process called 'synaptic plasticity', or the process by which neurons change their connectivity with other neurons in an activity-dependent manner. Using an adjunct to facilitate these changes in the EA population may improve TMS outcomes, including both implicit and explicit measures of suicide risk. The investigators\' previous data indicates that, in adults, the effects of a TMS protocol called intermittent theta-burst stimulation (iTBS) can be enhanced by pairing stimulation with a medication called D-Cycloserine. This FDA-approved medication leads to enhanced synaptic plasticity with iTBS. In adults, this combination led to greater improvements in depression symptoms and both implicit and explicit suicide risk. Implicit suicide risk is measured with a computerized test, called the death/suicide implicit association test (Death/Suicide IAT), and explicit suicide risk is defined as suicidal thoughts reported by the individual. In the current study, we aim to determine whether the effects of iTBS can be augmented with D-Cycloserine to reduce suicide risk in the EA population. Typical courses of iTBS involve daily treatments over 6 weeks, a timeframe that is not acceptable in individuals experiencing suicidal ideation. For this reason, we will build on data indicating that treatment courses can be condensed by delivering multiple treatments in a single day to accelerate symptomatic improvements. Specifically, our data suggests that (1) 4-weeks of daily iTBS+D-Cycloserine significantly improves implicit and explicit suicide risk and (2) a single-dose of D-Cycloserine paired with two iTBS treatments separated by one hour, enhances the physiological effects of iTBS. As such, in this study, participants will receive two treatments per day, separated by an hour, thereby accelerating a typical 4-week course to 2 weeks. Research Question and Objectives: To conduct a 2-week double-blind placebo-controlled randomized clinical trial where 54 participants will be randomly assigned to one of two groups: 1) accelerated iTBS+D-Cycloserine, and 2) accelerated iTBS+placebo. The primary outcome of the study is performance on the Death/Suicide-IAT, a measure of suicide risk; however, we will also determine whether pairing stimulation with D-Cycloserine enhances the antidepressant effects of iTBS, reduces suicidal ideation in this population, and reduces the likelihood of engaging in suicidal behavior or having suicidal crises over the following six months.
Recruiting0 awards Phase 23 criteria
More about Alexander McGirr, MD
Clinical Trial Related2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alexander McGirr, MD has experience with
- D-cycloserine
- ITBS Repetitive Transcranial Magnetic Stimulation (rTMS)
- Sham RTMS
- ITBS+D-Cycloserine
- Placebo Oral Capsule
- ITBS-DCS
Breakdown of trials Alexander McGirr, MD has run
Depression Treatment
Suicide and Self-Harm
Suicidal Thoughts and Behaviors
Suicide Attempt
Suicidal Thoughts
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alexander McGirr, MD specialize in?
Alexander McGirr, MD focuses on Depression Treatment and Suicide and Self-Harm. In particular, much of their work with Depression Treatment has involved treating patients, or patients who are undergoing treatment.
Is Alexander McGirr, MD currently recruiting for clinical trials?
Yes, Alexander McGirr, MD is currently recruiting for 2 clinical trials in Calgary Alberta. If you're interested in participating, you should apply.
Are there any treatments that Alexander McGirr, MD has studied deeply?
Yes, Alexander McGirr, MD has studied treatments such as D-cycloserine, iTBS repetitive Transcranial Magnetic Stimulation (rTMS), Sham rTMS.
What is the best way to schedule an appointment with Alexander McGirr, MD?
Apply for one of the trials that Alexander McGirr, MD is conducting.
What is the office address of Alexander McGirr, MD?
The office of Alexander McGirr, MD is located at: University of Calgary, Calgary, Alberta T2N 1N4 Canada. This is the address for their practice at the University of Calgary.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.